Thyroid Cancer Risk with GLP-1 Receptor Agonists: Evidence, Knowledge Gaps, and the Path Forward.
作者信息
Toro-Tobon David, Singh Ospina Naykky, Brito Juan P
机构信息
Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, Rochester, MN, USA.
Knowledge and Evaluation Research Unit, Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
出版信息
Thyroid. 2025 Jan;35(1):3-5. doi: 10.1089/thy.2024.0690. Epub 2025 Jan 8.
Abstract
摘要
相似文献
1
Thyroid Cancer Risk with GLP-1 Receptor Agonists: Evidence, Knowledge Gaps, and the Path Forward.胰高血糖素样肽-1受体激动剂与甲状腺癌风险：证据、知识空白及未来方向。
Thyroid. 2025 Jan;35(1):3-5. doi: 10.1089/thy.2024.0690. Epub 2025 Jan 8.
2
SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline.钠-葡萄糖协同转运蛋白 2 抑制剂或胰高血糖素样肽-1 受体激动剂治疗 2 型糖尿病成人患者：临床实践指南。
BMJ. 2021 May 11;373:n1091. doi: 10.1136/bmj.n1091.
3
Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.钠-葡萄糖共转运蛋白 2（SGLT-2）抑制剂和胰高血糖素样肽-1（GLP-1）受体激动剂治疗 2 型糖尿病：随机对照试验的系统评价和网络荟萃分析。
BMJ. 2021 Jan 13;372:m4573. doi: 10.1136/bmj.m4573.
4
Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.药物治疗 2 型糖尿病的获益与危害：随机对照试验的系统评价和网络荟萃分析。
BMJ. 2023 Apr 6;381:e074068. doi: 10.1136/bmj-2022-074068.
5
Glucagon-like peptide 1 (GLP-1) receptor agonists as a protective factor for incident depression in patients with diabetes mellitus: A systematic review.胰高血糖素样肽 1（GLP-1）受体激动剂作为糖尿病患者新发抑郁症的保护因素：系统评价。
J Psychiatr Res. 2023 Aug;164:80-89. doi: 10.1016/j.jpsychires.2023.05.041. Epub 2023 Jun 5.
6
Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies.胰高血糖素样肽-1受体激动剂与2型糖尿病患者的心力衰竭：随机和观察性研究的系统评价与荟萃分析
BMC Cardiovasc Disord. 2016 May 11;16:91. doi: 10.1186/s12872-016-0260-0.
7
Evaluating Thyroid Cancer Risk in Glucagon-like Peptide-1 Analog Users With Thyroid Nodules.评估甲状腺结节的胰高血糖素样肽-1类似物使用者的甲状腺癌风险。
J Surg Res. 2025 Aug;312:104-110. doi: 10.1016/j.jss.2025.05.016. Epub 2025 Jun 27.
8
Comparative efficacy of THR-β agonists, FGF-21 analogues, GLP-1R agonists, GLP-1-based polyagonists, and Pan-PPAR agonists for MASLD: A systematic review and network meta-analysis.THR-β 激动剂、FGF-21 类似物、GLP-1R 激动剂、GLP-1 为基础的多激动剂和全 PPAR 激动剂治疗 MASLD 的疗效比较：系统评价和网络荟萃分析。
Metabolism. 2024 Dec;161:156043. doi: 10.1016/j.metabol.2024.156043. Epub 2024 Sep 30.
9
Glucagon-like peptide-1 receptor agonists and pancreatic cancer risk: target trial emulation using real-world data.胰高血糖素样肽-1受体激动剂与胰腺癌风险：利用真实世界数据进行目标试验模拟
J Natl Cancer Inst. 2025 Mar 1;117(3):476-485. doi: 10.1093/jnci/djae260.
10
The quantity, quality and findings of network meta-analyses evaluating the effectiveness of GLP-1 RAs for weight loss: a scoping review.评估胰高血糖素样肽-1受体激动剂（GLP-1 RAs）减肥效果的网状Meta分析的数量、质量及结果：一项范围综述
Health Technol Assess. 2025 Jun 25:1-73. doi: 10.3310/SKHT8119.
本文引用的文献
1
Glucagon-Like Peptide 1 Receptor Agonists and Risk of Thyroid Cancer: An International Multisite Cohort Study.胰高血糖素样肽-1受体激动剂与甲状腺癌风险：一项国际多中心队列研究
Thyroid. 2025 Jan;35(1):69-78. doi: 10.1089/thy.2024.0387. Epub 2025 Jan 8.
2
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy.胰高血糖素样肽-1 受体：作用机制与治疗进展。
Signal Transduct Target Ther. 2024 Sep 18;9(1):234. doi: 10.1038/s41392-024-01931-z.
3
Shifting Trends in the Indication of Glucagon-like Peptide-1 Receptor Agonist Prescriptions: A Nationwide Analysis.胰高血糖素样肽-1受体激动剂处方适应症的变化趋势：一项全国性分析。
Ann Intern Med. 2024 Sep;177(9):1289-1291. doi: 10.7326/M24-0019. Epub 2024 Jul 23.
4
Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study.胰高血糖素样肽 1 受体激动剂的使用与甲状腺癌风险：斯堪的纳维亚队列研究。
BMJ. 2024 Apr 10;385:e078225. doi: 10.1136/bmj-2023-078225.
5
Glucagon-like peptide-1 receptor agonists and risk of thyroid cancer: A systematic review and meta-analysis of randomized controlled trials.胰高血糖素样肽-1 受体激动剂与甲状腺癌风险：一项随机对照试验的系统评价和荟萃分析。
Diabetes Obes Metab. 2024 Mar;26(3):891-900. doi: 10.1111/dom.15382. Epub 2023 Nov 29.
6
GLP-1 Receptor Agonists and the Risk of Thyroid Cancer.胰高血糖素样肽-1受体激动剂与甲状腺癌风险
Diabetes Care. 2023 Feb 1;46(2):384-390. doi: 10.2337/dc22-1148.
7
Use of GLP-1 Receptor Agonists and Occurrence of Thyroid Disorders: a Meta-Analysis of Randomized Controlled Trials.GLP-1 受体激动剂的使用与甲状腺疾病的发生：一项随机对照试验的荟萃分析。
Front Endocrinol (Lausanne). 2022 Jul 11;13:927859. doi: 10.3389/fendo.2022.927859. eCollection 2022.
8
National Trends in Use of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists by Cardiologists and Other Specialties, 2015 to 2020.2015 年至 2020 年，心脏病专家和其他专业医生使用钠-葡萄糖共转运蛋白 2 抑制剂和胰高血糖素样肽-1 受体激动剂的全国趋势。
J Am Heart Assoc. 2022 May 3;11(9):e023811. doi: 10.1161/JAHA.121.023811. Epub 2022 Apr 27.
9
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials.GLP-1 受体激动剂在 2 型糖尿病患者中的心血管、死亡率和肾脏结局：随机试验的系统评价和荟萃分析。
Lancet Diabetes Endocrinol. 2021 Oct;9(10):653-662. doi: 10.1016/S2213-8587(21)00203-5. Epub 2021 Aug 20.
10
A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.一项安慰剂对照试验评估皮下司美格鲁肽在非酒精性脂肪性肝炎中的疗效。
N Engl J Med. 2021 Mar 25;384(12):1113-1124. doi: 10.1056/NEJMoa2028395. Epub 2020 Nov 13.
Zotero 插件